WallStSmart

Perspective Therapeutics Inc. (CATX)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 2333045% more annual revenue ($20.63B vs $884,000). GEHC leads profitability with a 10.1% profit margin vs 0.0%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

CATX

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 3.31

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CATX.

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CATX3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.3110/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

CATX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$507.00M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-41.6%2/10

ROE of -41.6% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CATX

The strongest argument for CATX centers on Debt/Equity, Altman Z-Score, Price/Book.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : CATX

The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CATX carries more volatility with a beta of 1.80 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (60/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Perspective Therapeutics Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Perspective Therapeutics Inc. is an innovative biotechnology company specializing in the development of next-generation radiopharmaceuticals designed to treat various types of cancer. Utilizing cutting-edge radioisotope technologies, the company aims to enhance the efficacy of cancer treatments, thereby improving patient outcomes in a rapidly evolving market for targeted therapies. With a strong leadership team and strategic partnerships, Perspective Therapeutics is well-equipped to advance its mission and deliver breakthrough solutions that address the growing need for effective cancer interventions.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?